The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | G | Genito urinary system and sex hormones | |
| 2 | G03 | Sex hormones and modulators of the genital system | |
| 3 | G03A | Hormonal contraceptives for systemic use | |
| 4 | G03AA | Progestogens and estrogens, fixed combinations |
| Code | Title | |
|---|---|---|
| G03AA01 | Etynodiol and ethinylestradiol | |
| G03AA02 | Quingestanol and ethinylestradiol | |
| G03AA03 | Lynestrenol and ethinylestradiol | |
| G03AA04 | Megestrol and ethinylestradiol | |
| G03AA05 | Norethisterone and ethinylestradiol | |
| G03AA06 | Norgestrel and ethinylestradiol | |
| G03AA07 | Levonorgestrel and ethinylestradiol | |
| G03AA08 | Medroxyprogesterone and ethinylestradiol | |
| G03AA09 | Desogestrel and ethinylestradiol | |
| G03AA10 | Gestodene and ethinylestradiol | |
| G03AA11 | Norgestimate and ethinylestradiol | |
| G03AA12 | Drospirenone and ethinylestradiol | |
| G03AA13 | Norelgestromin and ethinylestradiol | |
| G03AA14 | Nomegestrol and estradiol | |
| G03AA15 | Chlormadinone and ethinylestradiol | |
| G03AA16 | Dienogest and ethinylestradiol | |
| G03AA17 | ||
| G03AA18 |
| Active Ingredient | Description | |
|---|---|---|
| Drospirenone and Estetrol |
Estetrol demonstrates anti-gonadotropic activity characterised by a dose-dependent decrease in both serum follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels. The progestogen drospirenone possesses progestagenic, antigonadotropic, antiandrogenic and mild antimineralocorticoid properties and has no oestrogenic, glucocorticoid or antiglucocorticoid activity. These properties are pharmacologically similar to the natural hormone progesterone. The contraceptive effect of drospirenone/estetrol is based on the interaction of various factors, the most important of which is inhibition of ovulation. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| AKIZZA Film coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| BREVINOR Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| CIMIZT Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| DROVELIS Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| ELOINE Film-coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| EVRA Plaster | European Medicines Agency (EU) | MPI, EU: SmPC | |
| FEMODENE ED Coated tablets | Health Products Regulatory Authority (ZA) | MPI, Generic | |
| LOETTE Tablet | Medicines and Medical Devices Safety Authority (NZ) | MPI, EU: SmPC | |
| MARVELON Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| MELODENE Coated tablet | Health Products Regulatory Authority (ZA) | MPI, Generic | |
| MICROGYNON Sugar-coated tablets | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| MINESSE Film-coated tablet | Health Products Regulatory Authority (ZA) | MPI, Generic | |
| MIRELLE Film-coated tablet | Health Products Regulatory Authority (ZA) | MPI, Generic | |
| NOVYNETTE Film-coated tablet | Health Products Regulatory Authority (ZA) | MPI, Generic | |
| PROGYLUTON Coated tablets | Marketing Authorisation Holder | MPI, EU: SmPC | |
| RIGEVIDON Coated tablet | Web Search | MPI, EU: SmPC | |
| XULANE Patch | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| YASMIN Film-coated tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
| ZOELY Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
